Haleon (HLN) EBITDA (2021 - 2025)

Haleon's (HLN) quarterly EBITDA came in at $1.6 billion in Q4 2025, down 24.72% on a QoQ basis from $2.1 billion in Q4 2023.

Haleon (HLN) EBITDA (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of EBITDA data on file, last reported at $1.6 billion in Q4 2025.

Quarterly EBITDA changed N/A year-over-year to $1.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 billion (changed N/A YoY) and the FY2025 annual result came in at $3.2 billion, down 10.52% from the prior year.
EBITDA eased to $1.6 billion in Q4 2025, from $2.1 billion in the prior quarter.
In the past five years, EBITDA ranged from a high of $2.1 billion in Q4 2023 to a low of $643.2 million in Q2 2023.
A 4-year average of $1.4 billion and a median of $1.6 billion in 2025 frame the typical range for EBITDA.
Annual changes were most pronounced in 2022 — EBITDA grew 2.75% — and 2023, when it grew 24.26%.
Tracing HLN's EBITDA over 4 years: stood at $1.7 billion in 2021, then grew by 2.75% to $1.7 billion in 2022, then grew by 24.26% to $2.1 billion in 2023, then fell by 24.72% to $1.6 billion in 2025.
The last three EBITDA figures came in at $1.6 billion (Q4 2025), $2.1 billion (Q4 2023), and $643.2 million (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Haleon	43.71 Bn	42.75 Bn	-	-
2	Teva Pharmaceutical Industries	43.11 Bn	39.45 Bn	2.15 Bn	-231.00 Mn
3	Zoetis	31.62 Bn	29.94 Bn	1.05 Bn	837.00 Mn
4	Takeda Pharmaceutical	28.72 Bn	22.92 Bn	5.10 Bn	1.26 Bn
5	United Therapeutics	22.33 Bn	19.67 Bn	683.80 Mn	330.80 Mn
6	Viatris	18.83 Bn	17.95 Bn	1.46 Bn	6.30 Mn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	151.50 Mn
8	Elanco Animal Health	12.10 Bn	11.57 Bn	798.00 Mn	248.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.25 Bn	7.60 Bn	397.90 Mn	18.35 Mn

Download Data